



A Comparative Study on Safety and Adverse Effect of Various 5-Ht3 Antagonist Drugs in Chemotherapy Patients at Tertiary Care Hospital

First and Corresponding Author: Dr. Vikas L, Assistant Professor, Mysore Medical College and Research Institute, Mysore 570001, India.

Email: yikilaxman@gmail.com

Received Date: 10/05/2023 **Revised Date:** 02/06/2023 **Accepted Date:** 27/06/2023

Abstract

Background: Chemotherapy has brought wonders to human race but also has got many adverse reactions. Out of which nausea and vomiting rank among top three adverse drug reactions. The desire to control chemotherapy induced nausea and vomiting (CINV) is strong that patients postpone or even refuse the treatment. Ondansetron and Granisetron are the most common drugs used for treatment of CINV. Hence this study is carried out to compare the efficacy and safety of these two drugs. **Methods:** This is a prospective observational study conducted in oncology department, KR Hospital, Mysuru. 150 participants who satisfied the inclusion criteria were enrolled for the study. Among them, 50 were given Ondansetron, 50 of them were given Granisetron and rest were given to Palonosetron for prevention of CINV. A well-designed data collection form was prepared to collect the data. Efficacy of antiemetics was assessed using NCI-CTC grading score. **Result:** The study showed that 20% experienced CINV while giving Granisetron plus Dexamethasone, 42% experienced CINV while giving Ondansetron plus Dexamethasone, 30% experienced CINV while giving Palonosetron plus Dexamethasone which indicates that Granisetron along with Dexamethasone is slightly better than the other. **Conclusion:** Though Granisetron regimen is found to be more effective, the choice of drug depends on the cost.

Keywords: Chemotherapy, Dexamethasone, Granisetron, Palonosetron, Nausea, Ondansetron, Vomiting.

Introduction: Cancer is a group of diseases that can start in any organ or tissue of the body characterized by uncontrolled growth and spread of abnormal cells to other part of the body. Though causes of cancer are not completely understood, numerous factors are known to increase the occurrence that includes modifiable and non-modifiable. These factors may act simultaneously or in sequence to initiate and /or promote cancer growth. Cancer is the second leading cause of morbidity and death globally. According to WHO 18.1 million new cases and 9.6 million deaths are reported in 2018. In developing and under developed countries, low access to the early detection and quality management of cancer due to less income is one of the reasons for mortality.^[1]

Treatment of cancer includes chemotherapy, radiotherapy and surgery. The types of treatment given depend on the type of cancer and the progression of the disease. Radiotherapy uses high dose of radiation to kill cancer cells and shrink tumours. Surgery is a procedure in which the tumour is removed from the body surgically.^[2] Chemotherapy uses chemicals to kill cancer cells or modify growing cells. There are many drugs used currently in which some are given as monotherapy and some are given in combination.^[3] The

development of chemotherapy has brought wonders to human race but also a new threat in the form of adverse drug reaction (ADRs) has been developed.^[4] These ADRs occur based on the type and amount of chemotherapy and how the body reacts to chemotherapy. Some of the common ADRs are fatigue, hair loss, myelosuppression, nausea and vomiting.^[5]

Chemotherapy induced nausea and vomiting is the most common ADR accounting up to 80%.^[6] The desire to avoid nausea and vomiting is so strong that patients have postponed or even refused to take treatment. CINV can impose limitation on the patient's ability function socially, maintain employment or complete daily activities.^[7] Frequent vomiting causes loss of body fluids and electrolyte imbalance. It also reduces tendency to eat or drink, if this continues it causes fatigue and weight loss. All these situations make the prevention of CINV an important part in cancer chemotherapy.^[8]

Different antiemetics are used based on CINV risk levels.

The most effective ones are 5-hydroxytryptamine₃ (5HT₃) receptor antagonist, neurokinin 1(NK-1) receptor antagonist and corticosteroids. And the drugs with lower therapeutic index include metoclopramide, butyrophenones, phenothiazines, cannabinoids, olanzapine and benzodiazepines. These antiemetics are given singly or in combination.^[9]

5- HT₃ antagonists are the most commonly used antiemetics for CINV prophylaxis that include Ondansetron, Granisetron, Dolasetron, and Palonosetron. The main adverse effects of these agents are mild head ache, transient elevation of aminotransferase levels, fatigue and constipation. The effect is increased when corticosteroids are given along with 5-HT₃ receptor antagonist.^[10] So, in this study we are comparing the efficacy and safety of Ondansetron, Granisetron and Palonosetron since these are the common antiemetics used for prevention of CINV in K.R Hospital.

Materials And Methods

This study is a prospective observational study conducted at oncology department, K.R Hospital, Mysuru. The study was carried out for one year, starting from 06/01/2021 to 31/01/2022. After attaining ethical clearance from Institutional Ethical Committee of K.R Hospital, 100 participants were chosen randomly for the study that satisfied the inclusion eligibility. Patients above 18 years of both sexes and who was receiving cancer chemotherapy were included. Patients who were not willing for the study were excluded. Data were collected from patient case note, treatment chart and patient or patients care taker interview and were documented in a suitably designed data collection form. Out of 150 participants, 50 were administered Granisetron 3mg plus Dexamethasone 8mg, 50 were given Ondansetron 8mg plus Dexamethasone 8mg and rest were given 0.25mg Palonosetron plus Dexamethasone 8mg intravenously as premedication. They were monitored and followed up. The grade score of nausea and vomiting of National Cancer Institute- Common Toxicity Criteria (NCI-CTC) and causality assessment of Naranjo Scale were used to evaluate the clinical outcome. The obtained data were recorded in MS Excel Sheet and was analysed.

Table 1: National Cancer Institute-Common Toxicity Criteria grading score.

NCI-CTC grade	Nausea	Vomiting
1	Loss of appetite without alteration in eating habits	1-2 episodes in 24hr
2	Oral intake decreased without significant weight loss, dehydration or malnutrition	3-5 episodes in 24 hr
3	Inadequate oral caloric or fluid intake, TPN or hospitalisation indicated	>=6 episodes in 24 hr, Tube feeding, TPN or hospitalisation indicated

4	-	Life threatening consequences; urgent intervention indicated
5	-	Death

G₀=No Nausea /No Vomiting

Results

Table 2: Effect of Antiemetic Treatment.

NCI-CTC GRADING	ONDANSETRON + DEXAMETHASONE	GRANISETRON + DEXAMETHASONE	PALONOSETRON + DEXAMETHASONE
G ₀	34	43	45
G ₁	4	5	3
G ₂	11	2	1
G ₃	1	0	0

Table 3: ADRs of Antiemetics.

SL. NO.	ADRs	GRANISETRON	ONDANSETRON	PALONOSETRON
1.	Fatigue	6	9	8
2.	Headache	2	2	4
3.	Constipation	2	2	2
4.	Diarrhoea	1	0	1
5.	Dizziness	0	1	1
6.	Asthenia	0	1	1
Total		11	15	17

Discussion

Females were predominant showing 61% and the most affected age group were above 50 years showing 51%. 89% of the participants were non-smokers and nonalcoholic. 27% of the participants had comorbidities. The major type of cancer was found to be breast cancer showing 31% followed by lung cancer (14%) and ovarian cancer (10%). Majorly used regimen was Paclitaxel and Carboplatin showing 26% followed by Doxorubicin and cyclophosphamide (19%). Doxorubicin induced emesis was found to be more showing 7%.

Out of 50 participants, who were receiving Granisetron plus Dexamethasone as antiemetic regimen for chemotherapy, 7 (14%) of them experienced vomiting. In that 5 (10%) of them showed G₁ and 2 (4%) of them showed G₂, which were assessed using NCI-CTC grading. In rest of the participants, who were receiving Ondansetron plus Dexamethasone, 16 (32%) of them experienced vomiting. In that 4 (8%) of them showed G₁, 11 (22%) of them showed G₂ and 1 (2%) of them showed G₃. The study showed that Granisetron plus Dexamethasone combination have slightly more efficacy when compared to Ondansetron / Palonosetron plus Dexamethasone combination. Similar study was carried out by Linda Stewart et al, in which they concluded that Granisetron is more effective than Ondansetron when used in combination with Dexamethasone in the prevention of acute and delayed vomiting caused by highly emetogenic chemotherapy.^[11]

There were no serious or unexpected adverse drug reactions. The study showed that Ondansetron induced maximum number of adverse drug reactions (57.6%). Out of which fatigue (60%) were predominant followed by headache, constipation, asthenia and dizziness. Granisetron induced 42.4% of total adverse drug reactions. Out of which fatigue were more

(54.5%) followed by headache, constipation and diarrhoea. All these are well established adverse drug reactions.

Adverse drug reactions were assessed using Naranjo Scale, in which most of the reactions were found to be possible (88.8%) and rest of them were found to be probable (11.1%). No much significance was seen in safety profile of both group of drugs. Similar study was done by A Stewart et al, in which they concluded that safety profile of Granisetron and Ondansetron showed no much significance.^[12]

Conclusion

Many clinical trials have been done over past decades to control CINV. The incidence and severity of CINV depends on the treatment and patient related factors. Many antiemetics have been used to prevent CINV based on these factors. Our study concluded that Granisetron plus Dexamethasone is effective than Ondansetron / Palonosetron plus Dexamethasone and there is not much difference in safety profile regime. Though Granisetron is recommended in patients receiving chemotherapy, the choice of the drug depends in the financial status as Granisetron is more expensive than Ondansetron.

Reference

1. WHO Cancer Fact sheet (Internet) Feb, 2015.
Available from <http://www.who.int/mediacentre/factsheets/fs297/en>.
2. Sijie BI. The rational basis for cancer chemotherapy. Anti-neoplastic agents. In Cragi's Modern Pharmacology with Clinical Applications, 5th ed, Little Brown and Company, New York, 1997; 659.
3. Lowenthal RM, Eaton K. Toxicity of chemotherapy. *Hematol-Oncol-Clin-North Am*, 1996 Aug; 10(40): 967.
4. Gilman A. "The initial clinical trial of nitrogen mustard". *Am.J.Surg*, May 1963; 105(5): 574.
5. Sanukhani JJ, Pawar P, Mittal R. Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience. *South Asian Journal of Cancer*. 2014; 2: 132-137.
6. Grundberg SM, Deuson RR, Movros P. Incidence of chemotherapy induced nausea and emesis after modern antiemetics. *Cancer*, 2004; 100: 2261-2268.
7. Lindley CM, Hirsch JD, O'Neill CV, et al. quality of life consequences of chemotherapy induced emesis. *Qual Life Res.*, 1992; 1: 331-340.
8. Saliahah N, Mazlan N, Lua PL. Chemotherapy induced nausea and vomiting: exploring patients' subjective experience. *J Multidiscip Healthc*, 2016; 9: 145-151.
9. Hesketh P. Chemotherapy induced nausea and vomiting. *N Engl J Med*, 2008; 358: 2482-2494.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, Version 1.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
11. Linda Stewart, M. Crawford, P.A. Taylor. The comparative effectiveness of ondansetron and Granisetron in a once daily dosage in the prevention of nausea and vomiting caused by cisplatin: a doubleblind clinical trial. *The Pharmaceutical Journal*, 2000; 265(7104): 59-62.
12. Stewart A, McQuade B, Cronje J. D. E, Goedhals L, Gudgeon A. Ondansetron compared with Granisetron in the prophylaxis of Cyclophosphamide induced Emesis in outpatients: A multicentre, double-blind, double-dummy, randomised parallel group study, 1995; 52: 202-210.